Improvement in symptoms of anxiety and depression in patients with atopic dermatitis after treatment with baricitinib

J. P. Thyssen; P. Lio; S. Ball; E. Pierce; L. Sun; Y. Chen; J. K.L. Tan; M. Augustin

doi:10.1111/jdv.17704

Improvement in symptoms of anxiety and depression in patients with atopic dermatitis after treatment with baricitinib

J. P. Thyssen, P. Lio, S. Ball, E. Pierce, L. Sun, Y. Chen, J. K.L. Tan, M. Augustin

Research output: Contribution to journal › Letter › peer-review

4 Scopus citations

Original language	English
Pages (from-to)	e147-e150
Journal	Journal of the European Academy of Dermatology and Venereology
Volume	36
Issue number	2
DOIs	https://doi.org/10.1111/jdv.17704
State	Published - Feb 2022
Externally published	Yes

Access to Document

10.1111/jdv.17704

Cite this

@article{637ee20b86d448a792ef908a2950f50a,

title = "Improvement in symptoms of anxiety and depression in patients with atopic dermatitis after treatment with baricitinib",

author = "Thyssen, {J. P.} and P. Lio and S. Ball and E. Pierce and L. Sun and Y. Chen and Tan, {J. K.L.} and M. Augustin",

note = "Funding Information: This study was sponsored by Eli Lilly and Company, under licence from Incyte Corporation. Funding Information: JPT has received compensation as a speaker, advisor or consultant for, or has received grant support from AbbVie, Eli Lilly and Company, LEO Pharma, Pfizer, Regeneron and Sanofi Genzyme. PL has received compensation as a speaker or advisor for, or received grant support from AbbVie, AOBiome, Dermavant, Eli Lilly and Company, Galderma, Johnson & Johnson, LEO Pharma, L{\textquoteright}Oreal, Micreos, Pfizer, Regeneron/Sanofi Genzyme, has received royalties from/has a licence with, and has planned patent with Theraplex AIM, and has stock options with Altus Labs and Micreos. SB, EP, LS and YC are employees and shareholders of Eli Lilly and Company. JKLT has received compensation as a consultant or advisor for, and travel support from Eli Lilly and Company. MA has received compensation as a consultant or speaker for, and has received grant support from AbbVie, Almirall, Beiersdorf, Eli Lilly and Company, Galderma, Incyte, LEO Pharma, Menlo, MSD, Novartis, Pfizer, Regeneron, Sanofi‐Genzyme and Trevi. ",

year = "2022",

month = feb,

doi = "10.1111/jdv.17704",

language = "English",

volume = "36",

pages = "e147--e150",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Improvement in symptoms of anxiety and depression in patients with atopic dermatitis after treatment with baricitinib

AU - Thyssen, J. P.

AU - Lio, P.

AU - Ball, S.

AU - Pierce, E.

AU - Sun, L.

AU - Chen, Y.

AU - Tan, J. K.L.

AU - Augustin, M.

N1 - Funding Information: This study was sponsored by Eli Lilly and Company, under licence from Incyte Corporation. Funding Information: JPT has received compensation as a speaker, advisor or consultant for, or has received grant support from AbbVie, Eli Lilly and Company, LEO Pharma, Pfizer, Regeneron and Sanofi Genzyme. PL has received compensation as a speaker or advisor for, or received grant support from AbbVie, AOBiome, Dermavant, Eli Lilly and Company, Galderma, Johnson & Johnson, LEO Pharma, L’Oreal, Micreos, Pfizer, Regeneron/Sanofi Genzyme, has received royalties from/has a licence with, and has planned patent with Theraplex AIM, and has stock options with Altus Labs and Micreos. SB, EP, LS and YC are employees and shareholders of Eli Lilly and Company. JKLT has received compensation as a consultant or advisor for, and travel support from Eli Lilly and Company. MA has received compensation as a consultant or speaker for, and has received grant support from AbbVie, Almirall, Beiersdorf, Eli Lilly and Company, Galderma, Incyte, LEO Pharma, Menlo, MSD, Novartis, Pfizer, Regeneron, Sanofi‐Genzyme and Trevi.

PY - 2022/2

Y1 - 2022/2

UR - http://www.scopus.com/inward/record.url?scp=85116024986&partnerID=8YFLogxK

U2 - 10.1111/jdv.17704

DO - 10.1111/jdv.17704

M3 - Letter

C2 - 34553429

AN - SCOPUS:85116024986

SN - 0926-9959

VL - 36

SP - e147-e150

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - 2

ER -